Department of Ophthalmology, University Hospitals UZ Leuven, Leuven, Belgium.
Research Group Ophthalmology, Department of Neurosciences, KU Leuven, Leuven, Belgium.
Am J Hypertens. 2024 Feb 15;37(3):179-198. doi: 10.1093/ajh/hpad111.
Glaucoma is one of the leading causes of global blindness and is expected to co-occur more frequently with vascular morbidities in the upcoming years, as both are aging-related diseases. Yet, the pathogenesis of glaucoma is not entirely elucidated and the interplay between intraocular pressure, arterial blood pressure (BP) and ocular perfusion pressure is poorly understood.
This systematic review aims to provide clinicians with the latest literature regarding the management of arterial BP in glaucoma patients.
A systematic search was performed in Medline, Embase, Web of Science and Cochrane Library. Articles written in English assessing the influence of arterial BP and systemic antihypertensive treatment of glaucoma and its management were eligible for inclusion. Additional studies were identified by revising references included in selected articles.
80 Articles were included in this systemic review. A bimodal relation between BP and glaucoma progression was found. Both high and low BP increase the risk of glaucoma. Glaucoma progression was, possibly via ocular perfusion pressure variation, strongly associated with nocturnal dipping and high variability in the BP over 24 h.
We concluded that systemic BP level associates with glaucomatous damage and provided recommendations for the management and study of arterial BP in glaucoma. Prospective clinical trials are needed to further support these recommendations.
青光眼是全球失明的主要原因之一,预计在未来几年内,随着两种疾病都与衰老有关,它将更频繁地与血管疾病同时发生。然而,青光眼的发病机制尚未完全阐明,眼压、动脉血压 (BP) 和眼灌注压之间的相互作用也知之甚少。
本系统评价旨在为临床医生提供有关青光眼患者动脉血压管理的最新文献。
在 Medline、Embase、Web of Science 和 Cochrane Library 中进行了系统检索。评估动脉血压和全身抗高血压治疗对青光眼及其管理影响的英文文章符合纳入标准。通过修订选定文章中包含的参考文献,确定了其他研究。
本系统评价共纳入 80 篇文章。发现血压与青光眼进展之间存在双峰关系。高和低血压都会增加青光眼的风险。青光眼的进展可能通过眼灌注压的变化,与夜间降压和 24 小时内血压的高变异性密切相关。
我们得出结论,全身血压水平与青光眼损害有关,并为青光眼的动脉血压管理提供了建议。需要前瞻性临床试验来进一步支持这些建议。